Neuronetics partners with Aetna to expand access to NeuroStar® Advanced Therapy for major depressive disorder (MDD). The previous psychotherapy trial requirement has been eliminated by Aetna’s healthcare policy update, which allows TMS treatment supervised by behavioral health nurse practitioners. This move by Aetna helps with early treatment interventions for mental health patients. Neuronetics is a leading medical technology company focusing on improving the quality of life for those suffering from neurological disorders.
Neuronetics, Inc. (NASDAQ: STIM), a leading medical technology company focused on enhancing the quality of life for patients with neurological disorders, has recently announced a significant healthcare policy update in partnership with Aetna. This update aims to increase patient access to the innovative NeuroStar® Advanced Therapy, a non-drug treatment developed by Neuronetics to address major depressive disorder (MDD) and improve mental health outcomes.
Effective immediately, Aetna has revised its policy to allow transcranial magnetic stimulation (TMS) treatment to be ordered and supervised by behavioral health nurse practitioners for patients diagnosed with major depressive disorder. Furthermore, the policy update eliminates the previous requirement for a four-month psychotherapy trial before a patient can qualify for the initial course of TMS treatment.
Keith J. Sullivan, President and CEO of Neuronetics Inc., expressed his enthusiasm about Aetna’s progressive approach: “Aetna’s decision to reduce access barriers for mental health treatments shows their commitment to helping patients at an earlier stage of their treatment journey. By opening doors to nurse practitioners and streamlining eligibility requirements, Aetna joins a growing list of payers dedicated to supporting those in need of mental health care.”
Aetna is a major player in the healthcare industry, covering over 16.8 million lives through its commercial policies nationwide. This policy update aligns with the recent trend among commercial and government payers to extend coverage for TMS Therapy. Notably, Neuronetics has also announced updated policies with other payers, including BlueCross BlueShield of Michigan, United HealthCare, and NGS Medicare.
Neuronetics stands out in the industry as the only TMS company with a dedicated health policy team, actively collaborating with providers and payers to advocate for essential health policy changes.
Major depressive disorder affects a significant number of adults in the United States, with a large proportion not adequately served by traditional antidepressant medications. NeuroStar TMS offers a non-drug treatment option that can alleviate the burden of drug-resistant depression. To learn more about NeuroStar TMS Therapy, please visit NeuroStar.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is just as crucial as physical health. As a global leader in neuroscience, Neuronetics pioneers the NeuroStar Advanced Therapy for Mental Health, redefining patient and physician expectations. NeuroStar is a non-drug, non-invasive treatment that significantly improves the quality of life for people suffering from neuro health conditions when conventional medication has proven ineffective. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). With over 5.4 million treatments delivered, NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults. It boasts the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics remains committed to transforming lives by offering exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.